REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedReviewHuman Subjects

Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study.

Mattingly T Joseph, Duru Emeka Elvis, Conti Rena M
Health affairs scholar2026DOI: 10.1093/haschl/qxag023
GLP-1 receptor agonistsglucagon-like peptide-1

Quality Score

6/10

Citations

0

Subjects

Human

PeptideVault Analysis

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of GLP-1 receptor agonists, glucagon-like peptide-1 in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Decent human data on GLP-1 receptor agonists, glucagon-like peptide-1. Not the final word, but a meaningful data point that adds to the weight of evidence.

Key Findings

The study found that GLP-1 receptor agonists were associated with a higher incidence of administration-related adverse events compared to insulin, particularly after supply shortages began in late 2022. The increase in reports was linked to both increased utilization and potential dosing errors.

Limitations

The study relies on voluntary reporting data which may not capture all adverse events accurately, lacks exposure denominators for risk assessment, and does not account for changes in prescribing patterns or patient behavior over time.

PeptideVault Analysis

Highlighting the safety concerns and educational needs surrounding the use of GLP-1 receptor agonists in clinical practice.

GLP-1 receptor agonistsglucagon-like peptide-1

GLP-1 Receptor Agonists: Safety Concerns and Patient Education Needs Highlighted

Published: May 16, 2026 | Source: Health affairs scholar (2026) | Category: GLP-1 receptor agonists, glucagon-like peptide-1

Overview

A new study published in Health Affairs Scholar has revealed that the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with a higher incidence of administration-related adverse events compared to insulin. This finding underscores the importance of patient and provider education, especially as supply shortages have affected availability.

Study Background

GLP-1 receptor agonists are increasingly used in clinical practice for their benefits in managing type 2 diabetes and obesity. However, concerns about safety issues have grown alongside their rapid adoption. Researchers sought to understand the nature and extent of adverse events reported through the FDA's Adverse Event Reporting System (FAERS) between January 2015 and December 2024.

What the Research Found

The study analyzed over 112,000 reports in FAERS data, focusing on GLP-1 receptor agonists and injectable insulin products. Key findings include:

  • Higher Incidence of Administration-Related Events: Among reported adverse events, GLP-1s were associated with a higher share (63%) of administration-related reactions compared to insulin (39%).
  • Increased Reports Post-Supply Shortages: The number of reports involving dosing issues and administration errors for GLP-1 receptor agonists increased significantly starting in Q4 2022, coinciding with national supply shortages.
  • Potential Impact of Increased Utilization: While the study suggests that some increase in reporting volume may reflect higher utilization rather than increased risk due to lack of exposure denominators, it highlights the need for ongoing surveillance.

What This Means for Peptide Users

The findings indicate a critical need for enhanced patient education and provider training on proper administration techniques. Patients using GLP-1 receptor agonists should be vigilant about dosing accuracy and seek guidance from healthcare providers if they encounter difficulties or adverse reactions. Providers are encouraged to closely monitor patients, especially during periods of supply shortages.

Limitations and Caveats

The study relies heavily on voluntary reporting data, which may not capture all adverse events accurately. Additionally, the lack of exposure denominators complicates risk assessment. The analysis also does not account for changes in prescribing patterns or patient behavior over time, which could influence reported outcomes.

How This Compares to Previous Research

Previous studies have highlighted potential side effects and safety concerns associated with GLP-1 receptor agonists but did not focus specifically on administration-related issues. This study provides a more detailed analysis of adverse events during the period of supply shortages, offering new insights into patient education needs and regulatory considerations.

Our Analysis

PeptideVault's assessment suggests that while this study highlights important safety concerns related to GLP-1 receptor agonists, it also underscores the need for ongoing research and surveillance. The findings are valuable in guiding clinical practice but should be interpreted with caution due to limitations inherent in voluntary reporting systems.

Key Takeaways

  • Enhanced Patient Education: Providers must ensure that patients understand proper administration techniques.
  • Regulatory Attention Needed: Continued regulatory oversight is essential, especially during periods of supply shortages.
  • Ongoing Surveillance: Post-marketing surveillance remains crucial for monitoring safety signals and adjusting clinical guidelines as necessary.

Original Source

Citation: Mattingly T Joseph, Duru Emeka Elvis, Conti Rena M (2026). Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study.. Health affairs scholar. DOI: 10.1093/haschl/qxag023

Access: https://pubmed.ncbi.nlm.nih.gov/41737498/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the PeptideVault research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on GLP-1 receptor agonists, explore our research guides.

Citation

Mattingly T Joseph, Duru Emeka Elvis, Conti Rena M. (2026). Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study.. Health affairs scholar. https://doi.org/10.1093/haschl/qxag023

View full text on PubMed

Related Papers

Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.

Sinha Binayak et al. · Obesity (Silver Spring, Md.) · 2025

A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.

Min Jee Sun et al. · Drug design, development and therapy · 2025

Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.

Rodriguez Patricia J et al. · JAMA network open · 2025

Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.

McCall Kenneth L et al. · Expert opinion on drug safety · 2026

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.

Liu Lulu et al. · Frontiers in endocrinology · 2022

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.